<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04782570</url>
  </required_header>
  <id_info>
    <org_study_id>Wuerzburg45/20-am</org_study_id>
    <secondary_id>PAN_VR</secondary_id>
    <nct_id>NCT04782570</nct_id>
  </id_info>
  <brief_title>Psychotherapy of Anxiety Disorders With Noninvasive Brain Stimulation - Using Virtual Reality</brief_title>
  <official_title>Nicht-invasive Hirnstimulation in Der Psychotherapie Von Angsterkrankungen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Wuerzburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to transfer the rTMS stimulation protocol by Raij et al. (2018) into&#xD;
      a therapeutic setting to improve exposure therapy in acrophobic patients. The&#xD;
      quasi-randomized, placebo-controlled and double-blinded study will include 88 patients with&#xD;
      height phobia (according to DSM 5). All participants will perform two exposure sessions in&#xD;
      virtual reality (VR). Before exposure therapy, one group will receive verum rTMS of the left&#xD;
      frontal cortex, which is indirectly functionally linked to the ventromedial prefrontal cortex&#xD;
      (Raij et al., 2018). The control group will receive sham stimulation. A structural MRI and a&#xD;
      TMS navigation system will be used for precise localization of the left FC. Anxiety symptoms&#xD;
      will be measured using subjective ratings (e.g. Acrophobia Questionnaire) and the behavioural&#xD;
      approach task (BAT) in VR and in real life before and after the treatment, and at 6 months&#xD;
      follow-up. Furthermore, blood samples will be collected before rTMS and after exposure&#xD;
      treatment to assess epigenetic and gene expression based changes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following hypotheses are derived:&#xD;
&#xD;
        1. Patients with acrophobia, who receive an active rTMS of the left FC before VRET, show a&#xD;
           significantly stronger reduction of phobic symptoms immediately after exposure therapy,&#xD;
           compared to the sham stimulation group.&#xD;
&#xD;
        2. Patients with acrophobia, who receive an active rTMS of the left FC before VRET, show a&#xD;
           significantly greater increase in approach behavior and significantly less distress&#xD;
           during the BAT immediately after exposure therapy, compared to the sham stimulation&#xD;
           group.&#xD;
&#xD;
        3. The postulated differences in hypotheses 1 and 2 are still detectable at follow-up after&#xD;
           6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective anxiety symptoms</measure>
    <time_frame>change from T1 (baseline /study start) to T4 (immediately after treatment)</time_frame>
    <description>Acrophobia Questionnaire (Cohen, 1977) with two subscales: 1) degree of anxiety (ACRO) and 2) degree of avoidance (AVOI) in height-related situations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective anxiety in behavioral approach tests (BAT)</measure>
    <time_frame>change from T1 (baseline /study start) to T4 (immediately after treatment)</time_frame>
    <description>anxiety measurement by a behavioral approach test (BAT) in virtual reality (glass elevator on the outside of an high-rise building, height up to 150m) and in real life (open stairwell height up to 11,6m).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective anxiety symptoms (Follow-Up)</measure>
    <time_frame>change from T1 (baseline/ study start) to T28 (6 months follow-up)</time_frame>
    <description>Acrophobia Questionnaire (Cohen, 1977) with two subscales: 1) degree of anxiety (ACRO) and 2) degree of avoidance (AVOI) in height-related situations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective anxiety in behavioral approach tests (BAT) (Follow-Up)</measure>
    <time_frame>change from T1 (baseline /study start) to T28 (6 months follow-up)</time_frame>
    <description>anxiety measurement by a behavioral approach test (BAT) in virtual reality (glass elevator on the outside of an high-rise building, height up to 150m) and in real life (open stairwell height up to 11,6m).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Phobia</condition>
  <arm_group>
    <arm_group_label>Verum TMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ITBS (intermittent Theta Burst Stimulation) over left frontal cortex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham TMS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham TMS over left frontal cortex</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Verum TMS</intervention_name>
    <description>Intensity of 100% of the resting motor threshold with iTBS. 600 stimuli applied in bursts of three pulses at 50 Hz given every 200 ms. iTBS will be applied 20 times for 2 s every 10 s.</description>
    <arm_group_label>Verum TMS</arm_group_label>
    <other_name>Cool-B70 A/P, MagPro X100, MagVenture速, Denmark</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham TMS</intervention_name>
    <description>Sham stimulation with same protocol, but without magnetic stimulation</description>
    <arm_group_label>Sham TMS</arm_group_label>
    <other_name>Cool-B70 A/P, MagPro X100,, MagVenture速, Denmark</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acrophobia (according to DSM-5)&#xD;
&#xD;
          -  Right handed&#xD;
&#xD;
          -  German native speaker&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neurological and/or severe physical illnesses&#xD;
&#xD;
          -  Comorbid Axis I disorder (other than phobias)&#xD;
&#xD;
          -  Pretreated phobia of heights&#xD;
&#xD;
          -  Use of tricyclic antidepressants, antipsychotics, or other substances that increase&#xD;
             cerebral seizure susceptibility&#xD;
&#xD;
          -  Craniocerebral injuries, head surgery&#xD;
&#xD;
          -  Epileptic seizures, or family history of epilepsy&#xD;
&#xD;
          -  Metal parts in the head area&#xD;
&#xD;
          -  Cardiac pacemakers&#xD;
&#xD;
          -  Infusion pumps&#xD;
&#xD;
          -  Heart diseases&#xD;
&#xD;
          -  Increased intracranial pressure&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Cochlear implants&#xD;
&#xD;
          -  Tattoos (done before the year 2000)&#xD;
&#xD;
          -  Piercings (if not completely removable)&#xD;
&#xD;
          -  Permanent make-up&#xD;
&#xD;
          -  Nicotine or pain patches&#xD;
&#xD;
          -  other MRI contraindications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin J. Herrmann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of W端rzburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin J. Herrmann, PhD</last_name>
    <phone>+49 931 201 76650</phone>
    <email>Herrmann_m@ukw.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Martin J. Herrmann</name>
      <address>
        <city>W端rzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin J. Herrmann</last_name>
      <phone>+49 931 201 76650</phone>
      <email>Herrmann_m@ukw.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.ukw.de/research/research-psychiatry/research-at-the-department-of-psychiatry/third-party-funded-projects/anxiety-non-invasive-brain-stimulation/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VR</keyword>
  <keyword>Exposure therapy</keyword>
  <keyword>Acrophobia</keyword>
  <keyword>rTMS</keyword>
  <keyword>PFC</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

